| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CFO and Cbo | Director | CFO & Head of Corp. Dev. +1 more
3 companies
Elena Ridloff is CFO and Cbo at SION, with reported holdings spanning 3 companies. Elena Ridloff's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $703K at current prices.
Our model assigns Elena Ridloff a middling insider score of 62/100, based on 14 past trades. Over a 12-month horizon, 81.8% of those trades were profitable, with an average 12-month return of +40.4%.
Elena Ridloff's largest disclosed position is in SION as CFO and Cbo, worth about $486K. The SION filings lean toward selling, a net 85,000 shares.
Elena Ridloff has 28 Form 4 filings on record from April 2019 to September 2026, across 4 companies: CFO and Cbo at Sionna Therapeutics (SION), 2025–2026; Director at Immunic (IMUX), 2026; Director at Kymera Therapeutics (KYMR), 2021–2026, and 1 more.
The 55 reported transactions were 22 open-market sales, 19 option or other derivative awards, 10 option exercises and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $6.6M.
The largest open-market sale was 36,000 shares of ACAD at an average $49.66 on December 9, 2019, about $1.8M.
All 7 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 3,000 | $87.00 | $261,000.00 | - | +29.1% | - | |
| Apr 1, 2026 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 12,000 | $85.39 | $1,024,660.38 | - | +35.0% | - | |
| Sep 2, 2025 | SION Sionna Therapeutics, Inc. | CFO & Head of Corp. Dev. | Sell10b5-1 | 9,584 | $25.09 | $240,441.52 | -19.9% | +53.4% | -71.2% | |
| Aug 28, 2025 | SION Sionna Therapeutics, Inc. | CFO & Head of Corp. Dev. | Sell10b5-1 | 23,416 | $25.70 | $601,857.86 | -32.7% | +70.3% | -77.2% | |
| Aug 20, 2025 | SION Sionna Therapeutics, Inc. | CFO & Head of Corp. Dev. | Sell10b5-1 | 52,000 | $21.62 | $1,124,335.00 | -42.1% | +71.8% | -75.8% | |
| Jun 11, 2025 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 4,500 | $50.00 | $225,000.00 | - | -10.1% | +71.4% | |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | Director | Sale+OE10b5-1 | 12,000 | $46.10 | $553,200.00 | - | -6.6% | +71.2% | |
| Apr 30, 2021 | ACAD Acadia Pharmaceuticals Inc | EVP and CFO | Sale+OE | 1,032 | $20.33 | $20,980.56 | -8.9% | +8.4% | -10.3% | |
| Feb 4, 2021 | ACAD Acadia Pharmaceuticals Inc | EVP and CFO | Sell | 2,051 | $50.61 | $103,801.11 | -19.7% | -62.2% | -54.0% | |
| Jan 6, 2021 | ACAD Acadia Pharmaceuticals Inc | EVP and CFO | Sale+OE | 1,016 | $53.34 | $54,193.44 | -20.7% | - | - |